Testosterone Cypionate Cardiovascular Impact Long-Term

What the TRAVERSE Trial Actually Shows About MACE Risk

The TRAVERSE trial (2023, N=5,204) is the largest placebo-controlled cardiovascular outcomes trial of testosterone therapy ever completed. Men aged 45 to 80 years with hypogonadism and either established cardiovascular disease or elevated cardiovascular risk were randomized to testosterone gel 1.62% (producing testosterone levels comparable to cypionate injections targeting mid-normal range) or placebo for a median 33 months. The primary endpoint, a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (HR 0.96, 95% CI 0.78 to 1.17), meeting the pre-specified non-inferiority margin of 1.5 [1].

That headline number matters. Prior observational studies produced conflicting signals, and the FDA required this trial before broadening testosterone labeling. TRAVERSE resolved the central question for MACE in a high-risk population.

What TRAVERSE Does Not Resolve

Non-inferiority for MACE does not mean "no cardiovascular signal." TRAVERSE found statistically significant higher rates of atrial fibrillation (3.5% vs. 2.4%) and pulmonary embolism (0.9% vs. 0.5%) in the testosterone arm [1]. These signals survived pre-specified secondary analysis.

Clinicians prescribing testosterone cypionate should communicate both findings to patients: the absence of excess heart attack and stroke risk, paired with the real excess risk for arrhythmia and thromboembolic events.

Translating Gel Data to Cypionate Injections

TRAVERSE used a transdermal gel, not testosterone cypionate. Cypionate injections produce wider peak-to-trough swings in serum testosterone than daily gel application. Peak levels after a 200 mg cypionate injection can exceed 1,500 ng/dL at 48 to 72 hours before falling toward 300 to 400 ng/dL by day 14 [2]. Those peaks drive hematocrit elevation more aggressively than stable transdermal levels. The TRAVERSE safety data are therefore a floor estimate for injection-based therapy, not a ceiling.

The T-Trials Cardiovascular Substudy: Coronary Plaque Signal

The Testosterone Trials (T-Trials, NEJM 2016, N=788 men aged 65 or older with total testosterone <275 ng/dL) were not powered for hard cardiovascular outcomes. However, a pre-specified cardiovascular substudy measured coronary artery calcium (CAC) and noncalcified plaque volume by CT angiography at baseline and 12 months [3].

Noncalcified plaque volume increased significantly more in the testosterone group than in the placebo group (mean difference 41 mm³, P<0.001). CAC score also progressed more in the testosterone arm. The T-Trials investigators stated: "The testosterone-treated group had a significantly greater increase in noncalcified plaque volume, raising concern about the cardiovascular safety of testosterone treatment in older men." [3]

Interpreting the Plaque Data Alongside TRAVERSE

These two datasets appear contradictory on the surface. TRAVERSE shows no excess MACE; T-Trials shows excess coronary plaque accrual. Several explanations have been proposed. First, the T-Trials substudy enrolled only 170 men, limiting statistical power for clinical event detection. Second, plaque volume changes over 12 months may not translate directly to 5-year or 10-year event rates. Third, the T-Trials population was older (mean age 72) with higher baseline cardiovascular burden than many TRT candidates.

The practical clinical takeaway: noncalcified plaque data from T-Trials argues for caution in men over 65 with pre-existing coronary disease, even though TRAVERSE did not show a MACE signal in a similarly high-risk cohort. Both datasets belong in any shared decision-making conversation.

What the Endocrine Society Guidelines Say

The 2018 Endocrine Society Clinical Practice Guideline on male hypogonadism states: "We suggest against initiating testosterone therapy in patients who are planning fertility in the near future or who have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, PSA >4 ng/mL, erythrocytosis (hematocrit >50%), untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia." [4]

That contraindication list places several cardiovascular conditions as absolute barriers to testosterone initiation, independent of the TRAVERSE non-inferiority finding.

Hematocrit Elevation and Thromboembolic Risk

Testosterone cypionate stimulates erythropoiesis through EPO-dependent and EPO-independent pathways. Hematocrit increases are dose-dependent and injection-frequency-dependent. A 2019 meta-analysis published in the Journal of Clinical Endocrinology and Metabolism (58 RCTs, N=5,601) found testosterone therapy increased hematocrit by a mean 3.18 percentage points (95% CI 2.37 to 3.99) compared to placebo [5].

Polycythemia (hematocrit above 50 to 54%, depending on the guideline used) occurred in 5.7% of testosterone-treated men versus 0.3% of controls in that same meta-analysis [5].

Why Cypionate Produces More Hematocrit Elevation Than Other Formulations

Peak serum testosterone after intramuscular cypionate injection is substantially higher than that achieved by daily topical gels or nasal gel formulations. Because erythropoietic stimulation correlates with testosterone peak concentration rather than average concentration, cypionate injections carry higher polycythemia risk per unit of average testosterone exposure than transdermal options [2].

Men receiving 200 mg cypionate every two weeks face greater hematocrit variability than those on 100 mg weekly schedules at equivalent total monthly dose. Splitting the dose and shortening the interval is the standard clinical intervention when hematocrit elevation becomes problematic before considering formulation change [4].

Monitoring Protocol for Hematocrit

Most guidelines, including the Endocrine Society 2018 guidance, recommend checking hematocrit at 3 months after initiation, then at 6 and 12 months, then annually. If hematocrit exceeds 54%, therapy should be withheld until levels normalize, the dose should be reduced, or the dosing interval should be extended. Therapeutic phlebotomy may be needed in some patients [4].

The American Urological Association's 2018 testosterone guideline echoes this threshold, citing increased thrombosis risk above 54% [6]. The elevated pulmonary embolism rate seen in TRAVERSE (0.9% vs. 0.5%) likely reflects at least partial contribution from polycythemia, though TRAVERSE did not publish a subgroup analysis stratified by hematocrit change.

Lipid Effects: HDL Suppression and LDL Variability

HDL Cholesterol

Testosterone cypionate consistently reduces HDL cholesterol. The 2019 meta-analysis of 58 RCTs cited above found a mean HDL reduction of 0.49 mmol/L (approximately 19 mg/dL) with testosterone therapy compared to placebo [5]. That magnitude is clinically meaningful, particularly in men with baseline HDL near 40 mg/dL.

The mechanism involves hepatic lipase upregulation, which accelerates HDL catabolism. Injectable testosterone formulations suppress HDL more than topical formulations, reflecting the first-pass hepatic exposure that occurs with high portal concentrations after intramuscular injection is metabolized [7].

LDL and Total Cholesterol

Effects on LDL are less consistent. The same meta-analysis found no statistically significant change in LDL across all trials combined. Some individual trials show mild LDL reduction; others show elevation. Aromatization of testosterone to estradiol may partly offset androgenic LDL effects. Clinicians should obtain a fasting lipid panel at baseline, at 3 months, and annually during therapy [4].

Triglycerides

Testosterone therapy modestly reduces triglycerides in men with metabolic syndrome or type 2 diabetes. A 12-month RCT published in Diabetes Care (N=199) found testosterone undecanoate reduced fasting triglycerides by 0.55 mmol/L versus placebo (P<0.001) in men with type 2 diabetes and hypogonadism [8]. Whether this benefit extends directly to cypionate formulations at typical TRT doses requires further study, but the triglyceride effect appears class-wide.

Blood Pressure Effects

The relationship between testosterone cypionate and blood pressure is modest and dependent on baseline status. Testosterone increases sodium retention through mineralocorticoid receptor activation and can increase extracellular fluid volume, particularly at supraphysiologic doses [9].

In TRAVERSE, blood pressure was not reported as a primary safety outcome, but hypertension-related adverse events were numerically similar between groups. The T-Trials primary paper reported no significant between-group difference in systolic blood pressure at 12 months [3].

When Blood Pressure Becomes a Concern

Supraphysiologic testosterone levels, which can occur in the 24 to 72 hours after a 200 mg cypionate injection, produce transient increases in blood pressure in some men. Men with pre-existing hypertension managed on renin-angiotensin-aldosterone system (RAAS) inhibitors may require closer monitoring of blood pressure in the first 3 months after testosterone initiation [9].

Estradiol, produced by aromatization of excess testosterone, also affects vascular tone and fluid retention. Aromatase inhibitor co-administration, sometimes prescribed to limit estradiol elevation during TRT, may paradoxically worsen cardiovascular risk by eliminating estradiol's vasculoprotective effects [10].

Atrial Fibrillation: The Emerging Signal

The TRAVERSE atrial fibrillation finding (3.5% vs. 2.4%, HR approximately 1.47) deserves clinical attention beyond MACE framing. Atrial fibrillation is an independent predictor of stroke, heart failure progression, and reduced quality of life [1].

The mechanism is not fully established. Proposed pathways include direct electrophysiologic effects of testosterone on atrial myocytes, left ventricular hypertrophy-mediated atrial dilation, and polycythemia-induced increased blood viscosity affecting atrial hemodynamics. Animal data suggest testosterone shortens atrial effective refractory period, increasing atrial fibrillation susceptibility [11].

Screening Before Initiation

Men with a history of paroxysmal atrial fibrillation, left atrial enlargement on echocardiogram, or uncontrolled hypertension represent a subgroup where the atrial fibrillation signal from TRAVERSE may argue for choosing a non-injectable formulation with stable testosterone levels over cypionate injections.

Routine pre-treatment ECG is not universally recommended by current guidelines, but the TRAVERSE data provide a reasonable basis for obtaining one in men over 60 with cardiovascular risk factors before starting cypionate therapy.

Venous Thromboembolism and the FDA Warning

The FDA added a labeling warning for venous thromboembolism (VTE) to all testosterone products in 2014, following post-marketing surveillance data and case series [12]. The TRAVERSE trial subsequently found higher pulmonary embolism rates (0.9% vs. 0.5%) in testosterone-treated men, lending prospective RCT support to the FDA's prior surveillance-based warning [1].

Deep vein thrombosis rates in TRAVERSE were numerically higher but did not reach statistical significance as an isolated endpoint. The combined VTE signal was part of the pre-specified secondary safety composite.

Men with known thrombophilia (factor V Leiden, prothrombin gene mutation, antiphospholipid syndrome) should not receive testosterone cypionate. The Endocrine Society guideline lists thrombophilia as an absolute contraindication [4]. Patients on anticoagulants for prior VTE require individualized risk-benefit discussion with their prescribing physician and cardiologist before any testosterone initiation.

Left Ventricular Hypertrophy and Cardiac Remodeling

Testosterone has direct anabolic effects on cardiac myocytes through androgen receptor-mediated pathways. Long-term supraphysiologic exposure, as seen in anabolic steroid abuse, causes pathological left ventricular hypertrophy (LVH), reduced diastolic function, and increased arrhythmia burden [13].

Physiologic testosterone replacement (targeting mid-normal range, 400 to 700 ng/dL) does not reliably produce pathological LVH in clinical trials. The T-Trials found no significant change in left ventricular mass at 12 months [3]. However, men who self-administer testosterone cypionate at doses well above replacement (200 to 400 mg weekly, targeting levels of 1,000 to 2,000 ng/dL) enter supraphysiologic territory where remodeling risk increases substantially.

Dose Matters More Than Duration

Echocardiographic studies of competitive bodybuilders using anabolic steroids at doses 5 to 20 times physiologic replacement show interventricular septum thickness averaging 13 to 14 mm versus 9 to 10 mm in age-matched controls [13]. That structural change increases sudden cardiac death risk. For patients on supervised TRT at replacement doses, this risk trajectory does not apply. The clinical boundary is approximate serum testosterone above 1,000 ng/dL as a persistent trough or above 1,500 ng/dL as a measured peak.

HealthRX Clinical Decision Framework for Cardiovascular Risk Stratification Before Testosterone Cypionate

Before initiating testosterone cypionate, a structured pre-treatment cardiovascular risk assessment reduces adverse outcomes. The HealthRX medical team uses the following stepwise approach:

Step 1. Confirm true hypogonadism. Two fasting morning testosterone levels below 300 ng/dL on separate days, with symptoms. Do not treat borderline values without symptoms.

Step 2. Stratify cardiovascular risk. Obtain 10-year ASCVD risk score (pooled cohort equations), resting blood pressure, fasting lipid panel, fasting glucose or HbA1c, and ECG if age >55 or known arrhythmia history.

Step 3. Apply contraindications. Screen for hematocrit >50%, untreated sleep apnea, recent MI or stroke within 6 months, uncontrolled heart failure, thrombophilia, and active prostate cancer [4].

Step 4. Choose formulation based on risk profile. Men with elevated ASCVD risk or baseline hematocrit 46 to 50% may benefit from daily topical gel rather than biweekly cypionate injections to minimize peak-concentration-driven hematocrit elevation.

Step 5. Set a monitoring schedule. Hematocrit and lipids at 3 months. Serum testosterone (trough if on injections) at 3 months, targeting 400 to 700 ng/dL. Annual lipid panel and hematocrit thereafter. Blood pressure at every visit.

Step 6. Communicate the TRAVERSE data explicitly. Document shared decision-making that addresses non-inferiority for MACE, the atrial fibrillation signal, and the pulmonary embolism signal.

Monitoring Parameters and Dose Adjustments: A Practical Reference

Testosterone Trough Targets

For testosterone cypionate injected every 7 days (100 mg/week), trough (pre-injection) testosterone should target 400 to 600 ng/dL. For every-14-day protocols (200 mg/2 weeks), trough levels often fall below 300 ng/dL by day 12 to 14, which is why most endocrinologists prefer weekly or twice-weekly dosing for pharmacokinetic consistency [2].

When to Hold or Reduce Dosing

Hematocrit above 54% requires therapy interruption until levels fall below 50% [4]. Symptomatic hypertension not controlled with RAAS adjustment, new-onset atrial fibrillation, or any VTE event warrants discontinuation and specialist consultation before any restart.

Long-Term Lipid Management

Men on testosterone cypionate with HDL below 35 mg/dL and LDL above 130 mg/dL may need statin therapy regardless of ASCVD risk score, given the combined lipid burden. The ACC/AHA 2019 cholesterol guideline includes testosterone as a risk-enhancing factor in its decision algorithm [14].